Sleep Disturbances: Implications for Cannabis Use, Cannabis Use Cessation, and Cannabis Use Treatment

Current Addiction Reports

Volumn 1, Issue 2, 2014, Pages 109-114

  Babson, Kimberly A ^a,b   Bonn Miller, Marcel O ^a,c,d  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cannabis; Cannabis treatment; Cannabis use disorders; Cannabis withdrawal; Insomnia; Sleep; Sleep disturbances

Indexed keywords

EID: 84914103419     PISSN: None     EISSN: 21962952     Source Type: Journal    
DOI: 10.1007/s40429-014-0016-9     Document Type: Review

References (66)

1. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: summary of national findings, NSDUH series H-41. Rockville: Substance Abuse and Mental Health Services Administration; 2011.
2. Gfroerer J, Epstein J. Marijuana initiates and their impact on future drug abuse treatment need. Drug Alcohol Depend. 1999;54:229–37.
3. Roffman R, Stephens R. Cannabis dependence: its nature, consequences and treatment. Cambridge: Cambridge University Press; 2006.
4. Budney A, Radonovich K, Higgins S, Wong C. Adults seeking treatment for marijuana dependence: a comparison with cocaine-dependent treatment seekers. Exp Clin Psychopharmacol. 1998;6:419–26.
5. Moore B, Budney A. Relapse in outpatient treatment for marijuana dependence. J Subst Abuse Treat. 2003;25:85–9.
6. Stephens R, Roffman R, Simpson E. Adult marijuana users seeking treatment. J Consult Clin Psychol. 1993;61:1100–4.
7. Marijuana Treatment Project Research Group. Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol. 2004;72:455–66.
8. Monti J. Hypnoticlike effects of cannabidiol in the rat. Psychopharmacology. 1977;55:263–5.
9. Bolla K, Lesage S, Gamalso C, Neubauer D, Funderburk F, Cadet J, et al. Sleep disturbance in heavy marijuana users. Sleep. 2008;31:901–8.
10. Fusar-Poli P, Crippa J, Bhattacharyya S, Borgwardt S, Allen P, Martin-Santos R, et al. Distinct effect of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009;66:95–105.
11. Murillo-Rodriguez E, Blanco-Centurion C, Sanchez C, Piomello D, Shiromani P. Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study. Sleep. 2003;26:943–7.
12. Cousens K, DiMascio A. Delta 9 THC as an hypnotic. An experimental study of three dose levels. Psychopharmacologia. 1973;33:355–64.
13. Tassinari C, Ambrosetto G, Peraita-Adrado MR, Gastaut H. The neuropsychiatric syndrome of delta-9-tetrahydrocannabinol and cannabis intoxication in naïve subjects: a clinical and polygraphic study during wakefulness and sleep. In: Braude M, Szara S, editors. Pharmacology of marijuana. New York: Raven; 1976. p. 357–75.
14. Gillin J, Kotin J, Post R. Sleep during one week of administration of delta-9-tetrahydrocanabinol to psychiatric patients. J Sleep Res. 1972;1:44.
15. Bobon D, Schulz H, Mattke D, Simonova O. Influence of synthetic-8-tetrahydrocannabinol on all-night sleep EEG in man. In: Jovanovic U, editor. The nature of sleep. Stuttgart: Fischer; 1973.
16. Weisz D, Gunnell D, Teyler T, Vardaris R. Changes in hippocampal CA1 population spikes following administration of delat-9-THC. Brain Res Bull. 1982;8:155–62.
17. Nicholson A, Turner C, Stone B, Robson P. Effect of Δ-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol. 2004;24:305–13.
18. Moreton J, Davis W. Electroencephalographic study of the effects of tetrahydrocannabinols on sleep in the rat. Neuropharmacology. 1973;12:897–907.
19. Bolla K, Brown K, Eldreth D, Tate K, Cadet J. Dose-related neurocognitive effects of marijuana use. Neurology. 2002;59:1337–43.
20. Chuah Y, Venlatraman V, Dinges D, Chee M. The neural basis of interindividual variability in inhibitory efficiency after sleep deprivation. J Neurosci. 2006;26:7156–62.
21. Drummond S, Smith M, Orff H, Chengazi V, Perlis M. Functional imaging of the sleeping brain: review of findings and implications for the study of insomnia. Sleep Med Rev. 2004;8:227–42.
22. Muzur A, Pace-Schott E, Hobson J. The prefrontal cortex in sleep. Trends Cogn Sci. 2002;6:475–81.
23. Eldreth D, Matochik J, Cadet J, Bolla K. Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. Neuroimaging. 2004;23:914–20.
24. Volkow N, Gillespie H, Mullani N, Tancredi L, Grant C, Valentine A, et al. Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication. Psychiatry Res. 1996;67:29–38.
25. Boden MT, Babson KA, Vujanovic AA, Short NA, Bonn-Miller MO. Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence. Am J Addict. 2013;22:277–84.
26. Bonn-Miller MO, Vujanovic AA, Feldner MT, Bernstein A, Zvolensky MJ. Posttraumatic stress symptom severity predicts marijuana use coping motives among traumatic event-exposed marijuana users. J Trauma Stress. 2007;20:577–86.
27. Buckner JD, Schmidt NB, Bobadilla L, Taylor J. Social anxiety and problematic cannabis use: evaluating the moderating role of stress reactivity and perceived coping. Behav Res Ther. 2006;44:1007–15.
28. Passie T, Emrich HM, Karst M, Brandt SD, Halpern JH. Mitigation of post-traumatic stress symptoms by cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Anal. 2012;4:649–59.
29. Cooper M. Motivations for alcohol use among adolescents: Development and validation of a four-factor model. Psychol Assess. 1994;6:117–28.
30. Fox C, Towe S, Stephens R, Walker D, Roffman R. Motives for cannabis use in high-risk adolescent users. Psychol Addict Behav. 2011;25:492–500.
31. Hides L, Lubman D, Cosgrave E, Buckby J, Killackey E, Yung A. Motives for substance use among young people seeking mental health treatment. Early Interv Psychiatr. 2008;2:188–94.
32. Johnson K, Mullin J, Marshall E, Bonn-Miller M, Zvolensky M. Exploring the mediational role of coping motives for marijuana use in terms of the relation between anxiety sensitivity and marijuana dependence. Am J Addict. 2010;19:277–82.
33. Bonn-Miller MO, Babson KA, Vandrey R. Using cannabis to help you sleep: Heightened frequency of medical cannabis use among those with PTSD. Drug Alcohol Depend. 2014;136:162–5. Improvement in sleep is the primary motivation for medical cannabis use among medical cannabis users with elevated symptoms of PTSD.
34. Russo E, Guy G, Robson P. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers. 2007;4:1729–43.
35. Schierenbeck T, Riemann D, Berger M, Homyak M. Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Med Rev. 2008;12:381–9.
36. Halikas J, Weller R, Morse C, Hoffmann R. A longitudinal study of marijuana effects. Int J Addict. 1985;20:701–11.
37. Boys A, Marsden J, Strang J. Understanding reasons for drug use amongst young people: a functional perspective. Health Educ Res. 2001;16:457–69.
38. Reilly D, Didcott P, Swift W, Hall W. Long-term cannabis use: characteristics of users in an Australian rural area. Addiction. 1998;93:837–46.
39. Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA. Self-reported cannabis use characteristics, patterns, and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse. 2014;40:23–30.
40. Walsh Z, Callaway R, Belle-Isle L, Capler R, Kay R, Lucas P, et al. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Pol. 2013;24:511–6.
41. Schaub M, Fanghaenel K, Stohler R. Reasons for cannabis use: Patients with schizophrenia versus matched healthy controls. Aust N Z J Psychiatr. 2008;42:1060–5.
42. Bonn-Miller MO, Babson KA, Vujanovic AA, Feldner MT. Sleep problems and PTSD symptoms interact to predict marijuana use coping motives: a preliminary investigation. J Dual Diagn. 2010;6:111–22.
43. Budney A, Hughes J, Moore B, Novy P. Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry. 2001;58:917–24.
44. Budney A, Moore B, Vandrey R, Hughes J. The time course and significance of cannabis withdrawal. J Abnorm Psychol. 2003;112:393–402.
45. Budney A, Vandrey R, Hughes J, Thostenson J, Bursac Z. Comparison of cannabis and tobacco withdrawal syndrome. Am J Psychiatry. 2008;161:1967–77.
46. Budney A, Vandrey R, Hughes J, Moore B, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 2007;86:22–9.
47. Haney M, Ward A, Comer S, Foltin R, Fischman M. Abstinence symptoms following oral THC administration to humans. Psychopharmacology. 1999;141:385–94.
48. 9-tetrahydrocannabinol in humans. Psychopharmacology. 2002;164:407–15.
49. Haney M, Hart C, Vosburg S, Nasser J, Bennett A, Zubaran C, et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology. 2004;29:58–70.
50. Haney M, Hart C, Vosburg S, Comer S, Reed S, Foltin R. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology. 2008;197:157–68.
51. Vandrey R, Smith M, McCann U, Budney A, Curran E. Sleep disturbance and the effects of extended release zolpidem during cannabis withdrawal. Drug Alcohol Depend. 2011;117:38–44. Cannabis use cessation increases sleep disturbances, whereas intervention to address sleep problems attenuates this finding. Sleep interventions may be a beneficial addition to CUD treatment.
52. Haney M. Self-administration of cocaine, cannabis, and heroin in the human laboratory: benefits and pitfalls. Addict Biol. 2009;14:9–21.
53. Babson K, Boden M, Bonn-Miller M. The impact of perceived sleep quality and sleep efficiency/duration on cannabis use during a self-guided quit attempt. Addict Behav. 2013;38:2707–13. Veterans with poor sleep quality prior to a quit attempt have less of a reduction in cannabis use during a quit attempt compared with those with relatively better sleep.
54. Babson KA, Boden MT, Harris AHS, Stickle TR, Bonn-Miller MO. Poor sleep quality as a risk factor for lapse following a cannabis quit attempt. J Subst Abuse Treat. 2013;44:438–43. Veterans with poor sleep prior to a cannabis quit attempt are at greater risk of lapse/relapse to cannabis use within the first 2 days of the quit attempt.
55. Copersino M, Boyd S, Tashkin D, Huestis M, Heishman S, Dermans J, et al. Cannabis withdrawal among non treatment-seeking adult cannabis user. Am J Addict. 2006;15:8–14.
56. Levin K, Copersino M, Heishman S, Liu F, Kelly D, Boggs D, et al. Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend. 2010;111:120–7.
57. Haney M, Hart C, Vosburg S, Comer S, Reed S, Cooper Z, et al. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology. 2010;211:233–44.
58. Cooper Z, Foltin R, Hart C, Vosburg S, Comer S, Haney M. A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addict Biol. 2013;18:993–1002.
59. Morgenthaler T, Kraemer M, Alessi C, Friedman L, Boehlecke B, Brown T, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An AASM report. Sleep. 2006;29:1415–9.
60. Morin C, Culbert J, Schwartz S. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry. 1994;151:1172–80.
61. Roehrs T, Roth T. Insomnia pharmacotherapy. Neurotherapeutics. 2012;9:728–38.
62. Morin C, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA. 1999;28:991–9.
63. McClusky H, Milby J, Switzer P, William V, Wooten V. Efficacy of behavioral versus triazolam treatment in persistent sleep-onset insomnia. Am J Psychiatry. 1991;148:121–6.
64. Morin C, Vallieres A, Guay B, Ivers H, Savard J, Merette C, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia. A randomized controlled trial. JAMA. 2009;301:2005–15.
65. Currie S, Clark S, Hodgins D, El-Guebaly N. Randomized controlled trial of brief cognitive-behavioural interventions for insomnia in recovering alcoholics. Addiction. 2004;99:1121–32.
66. Arnedt J, Conroy D, Rutt J, Aloia M, Brower K, Armitage R. An open trial of cognitive-behavioral treatment for insomnia comorbid with alcohol dependence. Sleep Med. 2007;8:176–80.